Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-05

Clinical Trial Update: Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on Rufinamide as adjunctive therapy for refractory partial seizures in epilepsy patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rufinamide (Rufinamide)

Snippet

Sponsor: Eisai Inc. | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2013-02-05